Zymeworks (ZYME) Total Current Liabilities (2021 - 2026)
Zymeworks recorded quarterly Total Current Liabilities of $35.6 million in Q1 2026, down 15.76% quarter-over-quarter from $42.3 million in Q4 2025, and down 45.24% year-over-year from $65.1 million in Q1 2025.
Zymeworks' Total Current Liabilities history runs 6 years deep, the most recent figure standing at $35.6 million for Q1 2026.
- In Q1 2026, Total Current Liabilities fell 45.24% year-over-year to $35.6 million; the TTM figure through Mar 2026 stood at $35.6 million (down 45.24% YoY), while the FY2025 annual figure was $42.3 million, down 52.07% from the prior year.
- Total Current Liabilities came in at $35.6 million for Q1 2026 at Zymeworks, down from $42.3 million in the prior quarter.
- In the past five years, Total Current Liabilities ranged from a high of $95.6 million in Q4 2022 to a low of $35.6 million in Q1 2026.
- A 5-year average of $63.3 million and a median of $57.7 million in 2022 frame the typical range for Total Current Liabilities.
- Across the five-year window, Total Current Liabilities soared 58.34% in 2024 and slumped 52.07% in 2025, its largest moves.
- Zymeworks' Total Current Liabilities stood at $95.6 million in 2022, then sank by 41.69% to $55.8 million in 2023, then soared by 58.34% to $88.3 million in 2024, then sank by 52.07% to $42.3 million in 2025, then declined by 15.76% to $35.6 million in 2026.
- According to Business Quant data, Total Current Liabilities over the past three periods registered $35.6 million, $42.3 million, and $42.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 16.35 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 1.70 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 636.40 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 66.94 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 13.42 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 3.88 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 5.11 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 1.35 Bn |
| 10 | Zymeworks | 1.84 Bn | 1.47 Bn | - | 35.65 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 35.65 Mn |
| Dec 31, 2025 | 42.32 Mn |
| Sep 30, 2025 | 42.04 Mn |
| Jun 30, 2025 | 38.50 Mn |
| Mar 31, 2025 | 65.10 Mn |
| Dec 31, 2024 | 88.29 Mn |
| Sep 30, 2024 | 83.91 Mn |
| Jun 30, 2024 | 54.71 Mn |
| Mar 31, 2024 | 56.89 Mn |
| Dec 31, 2023 | 55.76 Mn |
| Sep 30, 2023 | 72.85 Mn |
| Jun 30, 2023 | 93.55 Mn |
| Mar 31, 2023 | 67.32 Mn |
| Dec 31, 2022 | 95.63 Mn |
| Sep 30, 2022 | 57.71 Mn |
| Dec 31, 2021 | 71.85 Mn |